Compare IDEXX Laboratories, Inc. (IDXX) vs Paycom Software Inc (PAYC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Paycom Software Inc — how do they compare? IDEXX Laboratories, Inc. trades at $518 (market cap $40.43B), while Paycom Software Inc trades at $232.22 (market cap $10.36B). The key difference: IDEXX Laboratories, Inc. is far larger — about 3.9× Paycom Software Inc's market cap, and Paycom Software Inc pays a 0.65% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold IDEXX Laboratories, Inc. for 46 Days and Paycom Software Inc for 84 Days on average.
| IDXX | PAYC | |
|---|---|---|
Market Cap | $40.43B | $10.36B |
Volume | 692,164 | 666,294 |
Sector | Health | Technology |
52-Week High | $766.68 | $240.52 |
52-Week Low | $504.70 | $113.59 |
Typical Hold Time | 46 Days | 84 Days |
Enterprise Value | $41.32B | $11.15B |
Dividend Yield | — | 0.65% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $513.14, up 1.28% with strong fundamentals including 25.03% net income margin and 74.21% ROE. The stock shows bearish technical signals but maintains consistent earnings beats and analyst consensus of $665 price target. Recent acquisition of CoVetAI expands AI capabilities in veterinary workflow intelligence, supporting long-term growth framework.
Outlook remains positive with revenue growth accelerating to $4.3B in 2025 and projected $4.6B in 2026. Key risks include foreign exchange headwinds and weaker U.S. veterinary visits. The 56.5% buy rating from analysts suggests continued confidence in the company's diagnostic innovation pipeline and recurring revenue economics.
Paycom Software (PAYC) trades at $229.90, up 2.83% today, with a bullish technical signal and strong earnings momentum after beating estimates for three consecutive quarters. The company reported robust Q2 2026 results with 10% revenue growth and raised full-year guidance, supported by a high gross profit margin of 83.67% and solid cash flow generation. Analyst sentiment is mixed but leans positive, with a consensus price target of $207.75.
The outlook remains favorable due to operational leverage and product innovation, though risks include competitive pressures and market volatility. Upside potential hinges on sustained earnings growth and institutional confidence, while any guidance miss or macroeconomic slowdown could pressure the stock.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Paycom Software Inc
Paycom is a fast-growing provider of payroll and human capital management, or HCM, software primarily targeting clients with 50-10,000 employees in the United States. Paycom was established in 1998 and services about 18,000 clients as of 2021, based on parent company grouping. Alongside its core payroll software, Paycom offers various HCM add-on modules, including time and attendance, talent management, and benefits administration.
Read more on PAYC →
